Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 110 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 110 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - nintedanib as esilate - capsules soft - nintedanib as esilate 100 mg - idiopathic pulmonary fibrosis ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf) in adults. systemic sclerosis-associated interstitial lung diseaseofev is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (ssc-ild).chronic fibrosing interstitial lung diseases with a progressive phenotypeofev is indicated in adults for the treatment of chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype

Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - nintedanib as esilate - capsules soft - nintedanib as esilate 150 mg - idiopathic pulmonary fibrosis ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf) in adults. systemic sclerosis-associated interstitial lung diseaseofev is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (ssc-ild).chronic fibrosing interstitial lung diseases with a progressive phenotypeofev is indicated in adults for the treatment of chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype

Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin; metformin hydrochloride - film coated tablets - empagliflozin 12.5 mg; metformin hydrochloride 500 mg - metformin and empagliflozin - jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control• in patients inadequately controlled on their maximally tolerated dose of metformin alone.• in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin.• in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin; metformin hydrochloride - film coated tablets - empagliflozin 12.5 mg; metformin hydrochloride 500 mg - metformin and empagliflozin - jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control• in patients inadequately controlled on their maximally tolerated dose of metformin alone.• in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin.• in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin; metformin hydrochloride - film coated tablets - empagliflozin 5 mg; metformin hydrochloride 500 mg - metformin and empagliflozin - jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control• in patients inadequately controlled on their maximally tolerated dose of metformin alone.• in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin.• in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

Iżrael - Ingliż - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin; metformin hydrochloride - film coated tablets - empagliflozin 5 mg; metformin hydrochloride 500 mg - metformin and empagliflozin - jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control• in patients inadequately controlled on their maximally tolerated dose of metformin alone.• in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin.• in patients already being treated with the combination of empagliflozin and metformin as separate tablets.